Biomedical Engineering Advancements after Management of Myelomeningocele Study (MOMS): A Narrative Review

Authors

DOI:

https://doi.org/10.5195/ijms.2022.1127

Keywords:

Myelomeningocele, Fetoscopic Surgery, Tissue Engineering, Tissue Scaffolds, Neural Tube Defect

Abstract

Spina bifida is a neural tube defect resulting from an incomplete closure of the caudal neuropore. The most debilitating form of spina bifida, myelomeningocele (MMC), can present with Chiari II malformation with concomitant hydrocephalus, bowel and bladder abnormalities, and impaired motor function of the lower limbs. The incidence rate of spina bifida is 3.4 per 10,000 live births reported within the US. On average, the US spends $1,176,000,000 annually on patient management and treatment. Advancements in the standard therapy, namely prenatal intervention pioneered by the Management of Myelomeningocele Study (MOMS), have aimed to reduce maternal and fetal complications, and yet complications were increased, calling for the need of further improvements. Beyond current standard interventions for MMC, the most promising developments have employed various biomedical methods ranging from isolated stem cell injections to biodegradable scaffold patches. These scaffolds can be biologic or synthetic and are often incorporated with bioactive proteins or stem cells. This review discusses the benefits and limitations of post-MOMS era biomedical engineering intervention articles found in 3 medical and biomedical databases consisting of systematic reviews, meta-analyses, randomized control trials, and experimental studies. After analysis of the advancements and limitations of these studies, a combination of materials could create a superior scaffold possessing watertight impermeability and cytocompatibility for successful coverage and host integration with minimal inflammation. Coupled with minimally invasive intra-amniotic injection delivery, an earlier mitigation could further prevent progression of poor neurologic outcomes, and possibly even regenerate neuronal tissue in patients with MMC.

References

Rochelle D, Frando M, Voto H, Baron K. Pediatric Rehabilitation. In: Maitin IB, Cruz E, editors. CURRENT Diagnosis & Treatment: Physical Medicine & Rehabilitation Eds. New York: McGraw-Hill; 2014.

Moldenhauer JS, Flake AW. Open fetal surgery for neural tube defects. Best Practice & Research Clinical Obstetrics & Gynaecology. 2019 Jul 1;58:121-32.

Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM. Spina bifida. Nature reviews Disease primers. 2015 Apr 30;1(1):1-8.

Castillo J, Lupo PJ, Tu DD, Agopian AJ, Castillo H. The National Spina Bifida Patient Registry: A Decade's journey. Birth defects research. 2019 Aug 15;111(14):947-57.

Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification—United States, 1995–2011. MMWR. Morbidity and mortality weekly report. 2015 Jan 16;64(1):1.

Adzick NS, Thom EA, Spong CY, Brock III JW, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. New England Journal of Medicine. 2011 Mar 17;364(11):993-1004.

Adzick N. S. (2012). Fetal surgery for myelomeningocele: trials and tribulations. Isabella Forshall Lecture. Journal of pediatric surgery, 47(2), 273–281.

Moldenhauer JS, Adzick NS. Fetal surgery for myelomeningocele: After the Management of Myelomeningocele Study (MOMS). In Seminars in Fetal and Neonatal Medicine. 2017 Dec 1; 22(6), 360-66.

Watanabe M, Jo JI, Radu A, Kaneko M, Tabata Y, Flake AW. A tissue engineering approach for prenatal closure of myelomeningocele with gelatin sponges incorporating basic fibroblast growth factor. Tissue Engineering Part A. 2010 May 1;16(5):1645-55.

Watanabe M, Li H, Roybal J, Santore M, Radu A, Jo JI, et al. A tissue engineering approach for prenatal closure of myelomeningocele: comparison of gelatin sponge and microsphere scaffolds and bioactive protein coatings. Tissue Engineering Part A. 2011 Apr 1;17(7-8):1099-110.

Watanabe M, Li H, Kim AG, Weilerstein A, Radu A, Davey M, et al. Complete tissue coverage achieved by scaffold-based tissue engineering in the fetal sheep model of Myelomeningocele. Biomaterials. 2016 Jan 1;76(1):133-43.

Brown EG, Saadai P, Pivetti CD, Beattie MS, Bresnahan JC, Wang A, et al. In utero repair of myelomeningocele with autologous amniotic membrane in the fetal lamb model. J Pediatr Surg. 2014; 49(1):133-38.

Brown EG, Keller BA, Lankford L, Pivetti CD, Hirose S, Farmer DL, et al. Age does matter: a pilot comparison of placenta-derived stromal cells for in utero repair of myelomeningocele using a lamb model. Fetal diagnosis and therapy. 2016;39(3):179-85.

Brown EG, Keller BA, Pivetti CD, Sitkin NA, Farmer DL, Bresnahan JC: Development of a locomotor rating scale for testing motor function in sheep. J Pediatr Surg. 2015;50(1):617-21.

Li X, Yuan Z, Wei X, Li H, Zhao G, Miao J, et al. Application potential of bone marrow mesenchymal stem cell (BMSCs) based tissue-engineering for spinal cord defect repair in rat fetuses with spina bifida aperta. Journal of Materials Science: Materials in Medicine. 2016 Apr 1;27(4):77.

Dionigi B, Brazzo III JA, Ahmed A, Feng C, Wu Y, Zurakowski D, et al. Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida. Journal of pediatric surgery. 2015 Jun 1;50(6):1037-41.

Feng C, Graham CD, Connors JP, Brazzo III J, Zurakowski D, Fauza DO. A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida. Journal of pediatric surgery. 2016 Jun 1;51(6):1010-13.

Annor AH, Tang ME, Pui CL, Ebersole GC, Frisella MM, Matthews BD, et al. Effect of enzymatic degradation on the mechanical properties of biological scaffold materials. Surgical endoscopy. 2012 Oct;26(10):2767-78.

Oria M, Tatu RR, Lin CY, Peiro JL. In vivo evaluation of novel PLA/PCL polymeric patch in rats for potential spina bifida coverage. Journal of surgical research. 2019 Oct 1;242:62-9.

Matta AK, Rao RU, Suman KN, Rambabu V. Preparation and characterization of biodegradable PLA/PCL polymeric blends. Procedia materials science. 2014 Jan 1;6(1):1266-70.

Tatu R, Oria M, Pulliam S, Signey L, Rao MB, Peiro JL, et al. Using poly (l?lactic acid) and poly (??caprolactone) blends to fabricate self?expanding, watertight and biodegradable surgical patches for potential fetoscopic myelomeningocele repair. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2019 Feb;107(2):295-305.

Kunpalin Y, Subramaniam S, Perin S, Gerli MF, Bosteels J, Ourselin S, Deprest J, De Coppi P, David AL. Preclinical stem cell therapy in fetuses with myelomeningocele: A systematic review and meta?analysis. Prenatal diagnosis. 2021 Feb;41(3):283-300.

Boehler RM, Graham JG, Shea LD. Tissue engineering tools for modulation of the immune response. Biotechniques. 2011 Oct;51(4):239-54.

Bergh E, Buskmiller C, Johnson A. The Future of Fetal Surgery. Obstetrics and Gynecology Clinics. 2021 Dec;48(4):745-758.

Downloads

Published

2022-04-25

How to Cite

Campbell, N. C., Trippel, S. B., & Nauman, E. A. (2022). Biomedical Engineering Advancements after Management of Myelomeningocele Study (MOMS): A Narrative Review. International Journal of Medical Students. https://doi.org/10.5195/ijms.2022.1127

Issue

Section

Review

Categories